newratings.com  Aug 13  Comment 
NEW YORK CITY (dpa-AFX) - Bristol-Myers Squibb Company (BMY) and Otsuka America Pharmaceutical, Inc. announced that the U.S. FDA has approved an update to the Sprycel (dasatinib) product labeling. The labeling now includes five-year efficacy and...
MedPage Today  Aug 10  Comment 
(MedPage Today) -- Recent developments of interest in cardiovascular medicine
FiercePharma  Aug 10  Comment 
Novartis is working hard to build up market share for new psoriasis med Cosentyx ahead of its forthcoming competition, and it's signed on '80s icon Cyndi Lauper to help.
FiercePharma  Aug 5  Comment 
Novartis is dealing with more regulatory pushback on its MS med Gilenya as the agency said it will update Gilenya's label to reflect cases of serious brain infections linked to the pill.
Market Intelligence Center  Aug 5  Comment 
The patented algorithms that power MarketIntelligenceCenter.com's Artificial Intelligence Center found a trading opportunity with Novartis AG (NVS) that should provide a 3.23% return in just 163 days. Sell one Jan. '16 call at the $100.00 level...
newratings.com  Aug 3  Comment 
BASEL (dpa-AFX) - Swiss drug maker Novartis AG (NVS) announced that it has completed the divestiture of its influenza vaccines business, including influenza vaccines development pipeline, to Australian specialty biopharmaceutical company CSL Ltd....
Benzinga  Aug 2  Comment 
CSL Limited acquired influenza vaccines business of Novartis (NYSE: NVS), including influenza vaccines development pipeline Basel, Switzerland, August 3, 2015 - Novartis today announced that it has completed effective July 31, 2015 the...
The Australian  Jul 31  Comment 
CSL’s shares are closing in on $100 after hurdles for its Novartis acquisition were cleared earlier than expected.
The Australian  Jul 30  Comment 
CSL has won required approvals for its $US275m acquisition of Novartis’ flu vaccine business, which will be renamed Seqirus.


Fuerralz? That's marvelously good to know.

Wikinvest © 2006, 2007, 2008, 2009, 2010, 2011, 2012. Use of this site is subject to express Terms of Service, Privacy Policy, and Disclaimer. By continuing past this page, you agree to abide by these terms. Any information provided by Wikinvest, including but not limited to company data, competitors, business analysis, market share, sales revenues and other operating metrics, earnings call analysis, conference call transcripts, industry information, or price targets should not be construed as research, trading tips or recommendations, or investment advice and is provided with no warrants as to its accuracy. Stock market data, including US and International equity symbols, stock quotes, share prices, earnings ratios, and other fundamental data is provided by data partners. Stock market quotes delayed at least 15 minutes for NASDAQ, 20 mins for NYSE and AMEX. Market data by Xignite. See data providers for more details. Company names, products, services and branding cited herein may be trademarks or registered trademarks of their respective owners. The use of trademarks or service marks of another is not a representation that the other is affiliated with, sponsors, is sponsored by, endorses, or is endorsed by Wikinvest.
Powered by MediaWiki